Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes
Related Posts
Engel P, Wu JJ. Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS. Exp Dermatol. 2025 Aug;34(8):e70146. doi: 10.1111/exd.70146. PMID:[...]
Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]
Makaroff KE, Van C, Grospe V, Edmunds L, Calfon-Press MA, Watson KE, Horwich T. Novel Virtual Reality Intervention for Stress Reduction Among Patients With or[...]